Novartis Company Insiders

Novartis' latest congressional trading

Novartis Management Team Effectiveness

The company has Return on Asset of 0.1009 % which means that on every $100 spent on assets, it made $0.1009 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2628 %, implying that it generated $0.2628 on every 100 dollars invested. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.13 in 2025. Return On Capital Employed is likely to drop to 0.14 in 2025. At this time, Novartis' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 73.5 B in 2025, whereas Intangible Assets are likely to drop slightly above 22.7 B in 2025. Net Income Applicable To Common Shares is likely to gain to about 9.8 B in 2025, whereas Common Stock Shares Outstanding is likely to drop slightly above 1.9 B in 2025.

Novartis Workforce Comparison

Novartis Profit Margins

The company has Net Profit Margin of 0.23 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.3 %, which entails that for every 100 dollars of revenue, it generated $0.3 of operating income.

Novartis AG ADR Benchmark Summation

Novartis Notable Stakeholders

The success or failure of an entity such as Novartis AG ADR often depends on how effective the management is. Novartis management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novartis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novartis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Novartis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novartis AG ADR. Check Novartis' Beneish M Score to see the likelihood of Novartis' management manipulating its earnings.

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.